热门资讯> 正文
小RFK下令FDA调查堕胎药米非司酮的安全性
2025-09-25 22:57
- HHS Secretary Robert F. Kennedy Jr has tasked the U.S. FDA with investigating the safety and efficacy of mifepristone, a drug used in medication abortions.
- The probe comes in response to requests from many state attorneys general.
- In a Sept. 19 letter to 22 state attorneys general that was recently made public, RFK Jr. and FDA Commissioner Marty Makary wrote the FDA would conduct "its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug."
- "This Administration will ensure that women's health is properly protected by thoroughly investigating the circumstances under which mifepristone can be safely dispensed," the letter added.
- The generic version of mifepristone is manufactured by GenBioPro, while the brand name, Mifeprex, is made by Danco. A risk evaluation and mitigation strategy (REMS) is included in its labeling.
- Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion.
More on CVS
- CVS Health: A Deeply Undervalued Giant Investors Keep Ignoring
- CVS Health Vs. UnitedHealth: Companies In Crises - Back United's Recovery
- CVS Health: Outlier In Healthcare Implosion - Further Margin Recovery Ahead
- CVS Health falls after six sessions of gain
- CVS subsidiary Omnicare initiates Chapter 11 in wake of improper billing lawsuit
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。